Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Accumulated Expenses (2019 - 2026)

Enliven Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $9.8 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $9.8 million for Q1 2026, down 20.65% from a year ago — trailing twelve months through Mar 2026 was $9.8 million (down 20.65% YoY), and the annual figure for FY2025 was $14.4 million, up 212.63%.
  • Accumulated Expenses reached $9.8 million in Q1 2026 per ELVN's latest filing, down from $14.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $14.4 million in Q4 2025 and bottomed at $1.0 million in Q1 2023.
  • Median Accumulated Expenses over the past 5 years was $6.3 million (2022), compared with a mean of $7.1 million.
  • The largest annual shift saw Accumulated Expenses crashed 78.51% in 2023 before it skyrocketed 1085.36% in 2024.
  • Over 5 years, Accumulated Expenses stood at $6.3 million in 2022, then crashed by 46.98% to $3.3 million in 2023, then soared by 38.49% to $4.6 million in 2024, then soared by 212.63% to $14.4 million in 2025, then crashed by 31.66% to $9.8 million in 2026.
  • Business Quant data shows Accumulated Expenses for ELVN at $9.8 million in Q1 2026, $14.4 million in Q4 2025, and $13.2 million in Q3 2025.